Holly Hagan
Holly Hagan, PhD, MPH
CDUHR - Director
CDUHR - Associate Director, Infectious Disease Epidemiology and Theory Core
NYU School of Global Public Health – Professor
PhD, Epidemiology, University of Washington
MPH, Epidemiology, University of Massachusetts, Amherst
BA, Russian Studies, The Evergreen State College
Research Interests
Epidemiology, Natural history, Prevention and treatment of HCV and HIV in PWID and MSM, Research methods and exploration of study bias
Holly Hagan trained as an infectious disease epidemiologist with an emphasis on methods to study disease causation and control. Her research has addressed the etiology, epidemiology, natural history, prevention and treatment of blood-borne and sexually transmitted infections in key populations in general and among people who use drugs (PWUD) in particular. She is skilled in research synthesis (systematic reviews and meta-analyses) and the methods of implementation science. She has designed and led a number of large observational and experimental studies related to blood-borne viral infections in PWUD, men who have sex with men (MSM), and heterosexuals at high risk of HIV. Dr. Hagan is a member of the WHO Global Burden of Disease Study Diseases and Injuries Group, she served on the Institute of Medicine Committee on the Prevention and Control of Viral Hepatitis in the United States, and have been an advisor to the US Department of Health and Human Services, the CDC, and the Canadian Institutes of Health on national programs to detect, diagnose and treat HCV infections.
Principal Investigator, Overdose Prevention in New York. Active
Principal Investigator, Addressing Hepatitis C and Hepatocellular Carcinoma: The Current and Future Epidemics. Completed
Principal Investigator, Collaborative Injection Drug Users Study III: Drug User Intervention Trial (CIDUS/DUIT). Completed
Principal Investigator, Etiology and Prevention of HCV in IDUs (SPIN Project). Completed
Principal Investigator, National HIV Behavioral Surveillance – New York City. Completed
Principal Investigator, National HIV Behavioral Surveillance Among High Risk Heterosexuals: New York City. Completed
Principal Investigator, National HIV Behavioral Surveillance Among Injection Drug Users: New York City. Completed
Principal Investigator, Reducing HIV Transmission by Promoting Sexual Health Among Drug Users. Completed
Principal Investigator, Study to Reduce Intravenous Exposures (STRIVE). Completed
Principal Investigator, Synthesis: HCV Epidemiology and Prevention in Drug Users. Completed
Principal Investigator, Transition to Injection Drug Use in New York State in the Era of Prescription Opioid Misuse. Completed


Jenkins RA, Hagan H (2019).
What is a rural opioid risk and policy environment?
International Journal of Drug Policy [Epub 2019 Nov 29]. doi: 10.1016/j.drugpo.2019.11.014.

Stevens ER, Nucifora KA, Hagan H, Jordan AE, Uyei J, Khan B, Dombrowski K, Des Jarlais D, Braithwaite RS (2019).
Cost-effectiveness of direct anti-viral agents for hepatitis C virus infection and a combined intervention of syringe access and medication assisted therapy for opioid use disorders in an injection drug use population
Clinical Infectious Diseases [Epub 2019 Aug 11]. doi: 10.1093/cid/ciz726.

Chikovani I, Ompad DC, Uchaneishvili M, Sulaberidze L, Sikharulidze K, Hagan H, VanDevanter NL (2019).
On the way to hepatitis C elimination in the Republic of Georgia – Barriers and facilitators for people who inject drugs for engaging in the treatment program: A formative qualitative study
PLoS One, 14 (4), e0216123. doi: 10.1371/journal.pone.0216123. PMCID: PMC6488087.

Khan B, Duncan I, Saad M, Schaefer D, Jordan A, Smith D, Neaigus A, Des Jarlais D, Hagan H, Dombrowski K (2018).
Combination interventions for hepatitis C and cirrhosis reduction among people who inject drugs: An agent-based, networked population simulation experiment
PLoS One, 13 (11), e0206356. doi: 10.1371/journal.pone.0206356. PMCID: PMC6264850.

Jordan AE, Perlman DC, Smith DJ, Hagan H (2018).
Application of an adapted PRECIS-2 instrument to assess efficacy- and effectiveness-study designs in a systematic review of intervention studies of the hepatitis C virus-care continuum among people who use drugs
Comparative Effectiveness Research, 8, 3-12. doi: 10.2147/CER.S145672.


Hagan H, Jordan AE, Neurer J, Cleland CM (2015).
Incidence of sexually transmitted hepatitis C virus infection in HIV-positive men who have sex with men
AIDS, 29 (17), 2335-2345. doi: 10.1097/QAD.0000000000000834. PMCID: PMC4640945.

Hagan H, Pouget ER, Des Jarlais DC, Lelutiu-Weinberger C (2008).
Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: The influence of time and place
American Journal of Epidemiology, 168 (10), 1099-1109. doi: 10.1093/aje/kwn237. PMCID: PMC2727245.

Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin JS, Alexander ER (2001).
Sharing of drug preparation equipment as a risk factor for hepatitis C
American Journal of Public Health, 91 (1), 42-46. doi: 10.2105/AJPH.91.1.42. PMCID: PMC1446500.

Dr. Hagan's MyBibliography Profile
Selected Press
The White House observed World Hepatitis Day 2014. Holly Hagan was one of 12 leaders recognized for domestic and global work in the prevention and treatment of viral hepatitis.